Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy September 2, 2025
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update August 13, 2025
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy June 9, 2025
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress June 2, 2025
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update May 14, 2025
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million April 28, 2025